Tetrabenazine in the treatment of Huntington's disease - PubMed (original) (raw)

Tetrabenazine in the treatment of Huntington's disease

Diana Paleacu. Neuropsychiatr Dis Treat. 2007.

Abstract

Tetrabenazine (TBZ), a catecholamine-depleting agent initially developed for the treatment of schizophrenia, when tested for other indications, has proven to be more useful for the treatment of a variety of hyperkinetic movement disorders. These disorders include neurological diseases characterized by abnormal involuntary movements such as chorea associated with Huntington's disease, tics in Tourette's syndrome, dyskinesias and dystonias in tardive dyskinesia, also primary dystonias and myoclonus. This review will include and discuss studies published during the period of 1960-2006 regarding the clinical efficacy and tolerability of TBZ in Huntington's disease (HD). It will also review the chemistry, pharmacokinetics and dynamics of the drug and its mechanism of action compared to that of reserpine, the only similar compound. This review emphasizes the advantage of TBZ over dopamine-depleting compounds used in the treatment of chorea and reveals its clinical efficacy and side effects.

Keywords: Huntington’s disease; chorea; tetrabenazine.

PubMed Disclaimer

Figures

Figure 1

Tetrabenazine, a benzoquinolizine derivative with the chemical name, 2-oxo-3-isobutyl-9,10-dimethoxy-1,2,3,4,6,7-hexahydrobenzo[a]quinolizine.

Similar articles

• Tetrabenazine therapy of dystonia, chorea, tics, and other dyskinesias.
  Jankovic J, Orman J. Jankovic J, et al. Neurology. 1988 Mar;38(3):391-4. doi: 10.1212/wnl.38.3.391. Neurology. 1988. PMID: 3279337 Clinical Trial.
• Tetrabenazine: Spotlight on Drug Review.
  Kaur N, Kumar P, Jamwal S, Deshmukh R, Gauttam V. Kaur N, et al. Ann Neurosci. 2016 Sep;23(3):176-185. doi: 10.1159/000449184. Epub 2016 Sep 9. Ann Neurosci. 2016. PMID: 27721587 Free PMC article. Review.
• Tetrabenazine for the treatment of chorea and other hyperkinetic movement disorders.
  Jankovic J, Clarence-Smith K. Jankovic J, et al. Expert Rev Neurother. 2011 Nov;11(11):1509-23. doi: 10.1586/ern.11.149. Expert Rev Neurother. 2011. PMID: 22014129 Review.
• Tetrabenazine in the treatment of hyperkinetic movement disorders.
  Kenney C, Jankovic J. Kenney C, et al. Expert Rev Neurother. 2006 Jan;6(1):7-17. doi: 10.1586/14737175.6.1.7. Expert Rev Neurother. 2006. PMID: 16466307 Review.
• Tetrabenazine.
  Fasano A, Bentivoglio AR. Fasano A, et al. Expert Opin Pharmacother. 2009 Dec;10(17):2883-96. doi: 10.1517/14656560903386292. Expert Opin Pharmacother. 2009. PMID: 19929707 Review.

Cited by

• Endocannabinoid Modulation in Neurodegenerative Diseases: In Pursuit of Certainty.
  Vasincu A, Rusu RN, Ababei DC, Larion M, Bild W, Stanciu GD, Solcan C, Bild V. Vasincu A, et al. Biology (Basel). 2022 Mar 14;11(3):440. doi: 10.3390/biology11030440. Biology (Basel). 2022. PMID: 35336814 Free PMC article. Review.
• Efficacy and Safety of Tetrabenazine in Reducing Chorea and Improving Motor Function in Individuals With Huntington's Disease: A Systematic Review.
  Vadlamani N, Ibrahimli S, Khan FA, Castillo JA, Amaravadi KSS, Nalisetty P, Khan S. Vadlamani N, et al. Cureus. 2024 Oct 14;16(10):e71476. doi: 10.7759/cureus.71476. eCollection 2024 Oct. Cureus. 2024. PMID: 39544557 Free PMC article. Review.
• Clinical assessment of the effect of tetrabenazine on functional scales in huntington disease: a pilot open label study.
  Fekete R, Davidson A, Jankovic J. Fekete R, et al. Tremor Other Hyperkinet Mov (N Y). 2012;2:tre-02-86-476-4. doi: 10.7916/D8DN43SC. Epub 2012 Aug 6. Tremor Other Hyperkinet Mov (N Y). 2012. PMID: 23439575 Free PMC article.
• Antidopaminergic treatment is associated with reduced chorea and irritability but impaired cognition in Huntington's disease (Enroll-HD).
  Harris KL, Kuan WL, Mason SL, Barker RA. Harris KL, et al. J Neurol Neurosurg Psychiatry. 2020 Jun;91(6):622-630. doi: 10.1136/jnnp-2019-322038. Epub 2020 Mar 30. J Neurol Neurosurg Psychiatry. 2020. PMID: 32229581 Free PMC article.
• The therapeutic potential of cell identity reprogramming for the treatment of aging-related neurodegenerative disorders.
  Smith DK, He M, Zhang CL, Zheng JC. Smith DK, et al. Prog Neurobiol. 2017 Oct;157:212-229. doi: 10.1016/j.pneurobio.2016.01.006. Epub 2016 Feb 1. Prog Neurobiol. 2017. PMID: 26844759 Free PMC article. Review.

References

1. 1. Ashcroft GW, Macdougall EJ, Barker PA. A comparison of tetrabenazine and chlorpromazine in chronic schizophrenia. J Ment Sci. 1961;107:287–93. - PubMed
2. 1. Asher SW, Aminoff MJ. Tetrabenazine and movement disorders. Neurology. 1981;31:1051–4. - PubMed
3. 1. Bartels M, Zeller E. Tetrabenazine (Nitoman) therapy of chronic spontaneous oral dyskinesia. A video- and EMG-controlled study. Eur Arch Psychiatry Neurol Sci. 1984;234:172–4. - PubMed
4. 1. Boghen DR, Lesser RL. Blepharospasm and hemifacial spasm. Curr Treat Options Neurol. 2000;2:393–400. - PubMed
5. 1. Brandrup E. Reserpin og tetrabenacin ved chorea Huntington. Nordisk Medicin. 1960;4:968–9.

LinkOut - more resources

• Full Text Sources

  • Dove Medical Press
  • Europe PubMed Central
  • PubMed Central

• Other Literature Sources

  • The Lens - Patent Citations Database